The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias

L B Hesson, T L Dunwell, W N Cooper, D Catchpoole, A T Brini, R Chiaramonte, M Griffiths, Andrew D Chalmers, E R Maher, F Latif

Research output: Contribution to journalArticle

79 Citations (Scopus)
75 Downloads (Pure)

Abstract

Background: The Ras-assocation family (RASSF) of tumour suppressor genes (TSGs) contains 10 members that encode proteins containing Ras-assocation (RA) domains. Several members of the RASSF family are frequently epigenetically inactivated in cancer, however, their role in leukaemia has remained largely uninvestigated. Also, RASSF10 is a predicted gene yet to be experimentally verified. Here we cloned, characterised and demonstrated expression of RASSF10 in normal human bone marrow. We also determined the methylation status of CpG islands associated with RASSF1-10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow samples. Results: COBRA and bisulphite sequencing revealed RASSF6 and RASSF10 were the only RASSF members with a high frequency of leukaemia-specific methylation. RASSF6 was methylated in 94% (48/51) B-ALL and 41% (12/29) T-ALL, whilst RASSF10 was methylated in 16% (8/51) B-ALL and 88% (23/26) T-ALL. RASSF6 and RASSF10 expression inversely correlated with methylation which was restored by treatment with 5-aza-2'deoxycytidine (5azaDC). Conclusion: This study shows the hypermethylation profile of RASSF genes in leukaemias is distinct from that of solid tumours and represents the first report of inactivation of RASSF6 or RASSF10 in cancer. These data show epigenetic inactivation of the candidate TSGs RASSF6 and RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia. This study also warrants further investigation of the newly identified RASSF member RASSF10 and its potential role in leukaemia.
Original languageEnglish
JournalMolecular Cancer
Volume8
Issue number42
DOIs
Publication statusPublished - 1 Jul 2009

Fingerprint

Tumor Suppressor Genes
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Leukemia
Methylation
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
decitabine
Bone Marrow
ras Proteins
Neoplasms
CpG Islands
Epigenomics
Genes

Cite this

Hesson, L. B., Dunwell, T. L., Cooper, W. N., Catchpoole, D., Brini, A. T., Chiaramonte, R., ... Latif, F. (2009). The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Molecular Cancer, 8(42). https://doi.org/10.1186/1476-4598-8-42

The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. / Hesson, L B; Dunwell, T L; Cooper, W N; Catchpoole, D; Brini, A T; Chiaramonte, R; Griffiths, M; Chalmers, Andrew D; Maher, E R; Latif, F.

In: Molecular Cancer, Vol. 8, No. 42, 01.07.2009.

Research output: Contribution to journalArticle

Hesson, LB, Dunwell, TL, Cooper, WN, Catchpoole, D, Brini, AT, Chiaramonte, R, Griffiths, M, Chalmers, AD, Maher, ER & Latif, F 2009, 'The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias', Molecular Cancer, vol. 8, no. 42. https://doi.org/10.1186/1476-4598-8-42
Hesson, L B ; Dunwell, T L ; Cooper, W N ; Catchpoole, D ; Brini, A T ; Chiaramonte, R ; Griffiths, M ; Chalmers, Andrew D ; Maher, E R ; Latif, F. / The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. In: Molecular Cancer. 2009 ; Vol. 8, No. 42.
@article{b769854dcfce48a79f35680c3c002177,
title = "The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias",
abstract = "Background: The Ras-assocation family (RASSF) of tumour suppressor genes (TSGs) contains 10 members that encode proteins containing Ras-assocation (RA) domains. Several members of the RASSF family are frequently epigenetically inactivated in cancer, however, their role in leukaemia has remained largely uninvestigated. Also, RASSF10 is a predicted gene yet to be experimentally verified. Here we cloned, characterised and demonstrated expression of RASSF10 in normal human bone marrow. We also determined the methylation status of CpG islands associated with RASSF1-10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow samples. Results: COBRA and bisulphite sequencing revealed RASSF6 and RASSF10 were the only RASSF members with a high frequency of leukaemia-specific methylation. RASSF6 was methylated in 94{\%} (48/51) B-ALL and 41{\%} (12/29) T-ALL, whilst RASSF10 was methylated in 16{\%} (8/51) B-ALL and 88{\%} (23/26) T-ALL. RASSF6 and RASSF10 expression inversely correlated with methylation which was restored by treatment with 5-aza-2'deoxycytidine (5azaDC). Conclusion: This study shows the hypermethylation profile of RASSF genes in leukaemias is distinct from that of solid tumours and represents the first report of inactivation of RASSF6 or RASSF10 in cancer. These data show epigenetic inactivation of the candidate TSGs RASSF6 and RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia. This study also warrants further investigation of the newly identified RASSF member RASSF10 and its potential role in leukaemia.",
author = "Hesson, {L B} and Dunwell, {T L} and Cooper, {W N} and D Catchpoole and Brini, {A T} and R Chiaramonte and M Griffiths and Chalmers, {Andrew D} and Maher, {E R} and F Latif",
year = "2009",
month = "7",
day = "1",
doi = "10.1186/1476-4598-8-42",
language = "English",
volume = "8",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "42",

}

TY - JOUR

T1 - The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias

AU - Hesson, L B

AU - Dunwell, T L

AU - Cooper, W N

AU - Catchpoole, D

AU - Brini, A T

AU - Chiaramonte, R

AU - Griffiths, M

AU - Chalmers, Andrew D

AU - Maher, E R

AU - Latif, F

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Background: The Ras-assocation family (RASSF) of tumour suppressor genes (TSGs) contains 10 members that encode proteins containing Ras-assocation (RA) domains. Several members of the RASSF family are frequently epigenetically inactivated in cancer, however, their role in leukaemia has remained largely uninvestigated. Also, RASSF10 is a predicted gene yet to be experimentally verified. Here we cloned, characterised and demonstrated expression of RASSF10 in normal human bone marrow. We also determined the methylation status of CpG islands associated with RASSF1-10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow samples. Results: COBRA and bisulphite sequencing revealed RASSF6 and RASSF10 were the only RASSF members with a high frequency of leukaemia-specific methylation. RASSF6 was methylated in 94% (48/51) B-ALL and 41% (12/29) T-ALL, whilst RASSF10 was methylated in 16% (8/51) B-ALL and 88% (23/26) T-ALL. RASSF6 and RASSF10 expression inversely correlated with methylation which was restored by treatment with 5-aza-2'deoxycytidine (5azaDC). Conclusion: This study shows the hypermethylation profile of RASSF genes in leukaemias is distinct from that of solid tumours and represents the first report of inactivation of RASSF6 or RASSF10 in cancer. These data show epigenetic inactivation of the candidate TSGs RASSF6 and RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia. This study also warrants further investigation of the newly identified RASSF member RASSF10 and its potential role in leukaemia.

AB - Background: The Ras-assocation family (RASSF) of tumour suppressor genes (TSGs) contains 10 members that encode proteins containing Ras-assocation (RA) domains. Several members of the RASSF family are frequently epigenetically inactivated in cancer, however, their role in leukaemia has remained largely uninvestigated. Also, RASSF10 is a predicted gene yet to be experimentally verified. Here we cloned, characterised and demonstrated expression of RASSF10 in normal human bone marrow. We also determined the methylation status of CpG islands associated with RASSF1-10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow samples. Results: COBRA and bisulphite sequencing revealed RASSF6 and RASSF10 were the only RASSF members with a high frequency of leukaemia-specific methylation. RASSF6 was methylated in 94% (48/51) B-ALL and 41% (12/29) T-ALL, whilst RASSF10 was methylated in 16% (8/51) B-ALL and 88% (23/26) T-ALL. RASSF6 and RASSF10 expression inversely correlated with methylation which was restored by treatment with 5-aza-2'deoxycytidine (5azaDC). Conclusion: This study shows the hypermethylation profile of RASSF genes in leukaemias is distinct from that of solid tumours and represents the first report of inactivation of RASSF6 or RASSF10 in cancer. These data show epigenetic inactivation of the candidate TSGs RASSF6 and RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia. This study also warrants further investigation of the newly identified RASSF member RASSF10 and its potential role in leukaemia.

UR - http://www.scopus.com/inward/record.url?scp=67651093725&partnerID=8YFLogxK

UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2711046

UR - http://www.molecular-cancer.com/content/8/1/42

U2 - 10.1186/1476-4598-8-42

DO - 10.1186/1476-4598-8-42

M3 - Article

VL - 8

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 42

ER -